Avidity Biosciences (Nasdaq:RNA) - Stock Price, News & Analysis

RNA Stock Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.

RNA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 66.2% below our estimate of its fair value

Revenue is forecast to grow 59.07% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Avidity Biosciences, Inc. Competitors

Merus

NasdaqGM:MRUS

US$2.6b

Vericel

NasdaqGM:VCEL

US$2.2b

Intellia Therapeutics

NasdaqGM:NTLA

US$2.0b

Kymera Therapeutics

NasdaqGM:KYMR

US$2.0b

Price History & Performance

Summary of all time highs, changes and price drops for Avidity Biosciences
Historical stock prices
Current Share Price	US$24.36
52 Week High	US$27.66
52 Week Low	US$4.83
Beta	0.77
1 Month Change	-4.55%
3 Month Change	93.18%
1 Year Change	96.45%
3 Year Change	3.92%
5 Year Change	n/a
Change since IPO	-14.53%

Recent updates

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans

Jun 07

Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Feb 22

Avidity Biosciences Has A Promising RNA Therapy Platform

Jan 13

Avidity inks research deal with Bristol Myers' subsidiary, gives 2021 pipeline updates

Jan 08

Shareholder Returns

	RNA	US Biotechs	US Market
7D	7.2%	-0.2%	2.9%
1Y	96.5%	-1.0%	22.2%

Return vs Industry: RNA exceeded the US Biotechs industry which returned -1% over the past year.

Return vs Market: RNA exceeded the US Market which returned 22.2% over the past year.

Price Volatility

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	10.9%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: RNA's share price has been volatile over the past 3 months.

Volatility Over Time: RNA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2012	253	Sarah Boyce	www.aviditybiosciences.com

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.

Avidity Biosciences, Inc. Fundamentals Summary

How do Avidity Biosciences's earnings and revenue compare to its market cap?
RNA fundamental statistics
Market cap	US$2.33b
Earnings (TTM)	-US$212.22m
Revenue (TTM)	US$9.56m

243.7x

P/S Ratio

-11.0x

P/E Ratio

Is RNA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNA income statement (TTM)
Revenue	US$9.56m
Cost of Revenue	US$190.97m
Gross Profit	-US$181.41m
Other Expenses	US$30.81m
Earnings	-US$212.22m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.22
Gross Margin	-1,897.57%
Net Profit Margin	-2,219.87%
Debt/Equity Ratio	0%

How did RNA perform over the long term?

See historical performance and comparison

RNA Stock Overview

Rewards

Risk Analysis

Avidity Biosciences, Inc. Competitors

NasdaqGM:MRUS

US$2.6b

NasdaqGM:VCEL

US$2.2b

NasdaqGM:NTLA

US$2.0b

NasdaqGM:KYMR

US$2.0b

Price History & Performance

Recent News & Updates

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Recent updates

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Growth Index

Avidity Biosciences, Inc. Supports World Facioscapulohumeral Muscular Dystrophy Day and Presents Preclinical Data from FSHD Program

Consensus forecasts updated

Price target decreased to US$45.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avidity Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Price target increased to US$49.80

Avidity Biosciences, Inc Appoints Michael MacLean as Chief Business Officer